105 results about "Adrenal insufficiency" patented technology

A device for treatment of mitral annulus dilation is disclosed, wherein the device comprises two states. In a first of these states the device is insertable into the coronary sinus and has a shape of the coronary sinus. When positioned in the coronary sinus, the device is transferable to the second state assuming a reduced radius of curvature, whereby the radius of curvature of the coronary sinus and the radius of curvature as well as the circumference of the mitral annulus is reduced.

This invention relates to devices and methods for the therapeutic changing of the geometry of the left ventricle of the human heart. Specifically, the invention relates to the left-ventricular lateral wall introduction of an anchoring device to align the papillary muscles.

Methods for using blood pumps to treat heart failure are disclosed. The pump is mounted on an interior of a stent, and the stent is releasably mounted on a distal end of a catheter. The distal end of the catheter is inserted into a peripheral artery and advanced to position at a region of interest within the descending aorta, the ascending aorta, or the left ventricle. The stent and the pump are released from the catheter, and the pump is activated to increase blood flow downstream of the pump. The pump can also be positioned in the vena cava or used to treat right-sided heart failure following the insertion of an LVAD, or to improve venous return in patients with varicose veins. Non-stent pumps are described for insertion between the pulmonary vein and aorta, and between the vena cava and pulmonary artery designed for use during cardiac surgery.

A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.

According to a first aspect the invention relates to the use of fumaric acid derivatives selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds and mixtures thereof for preparing a drug for the treatment or prevention of cardiac insufficiency, in particular left ventricular insufficiency, myocardial infarction and angina pectoris.According to a second aspect the invention relates to the use of fumaric acid derivatives, selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds and mixtures thereof for preparing a drug for the treatment of asthma and chronic obstructive pulmonary diseases, especially asthma caused by allergies, infections, analgesics, job conditions or physical effort, mixed forms of asthma, or asthma cardiale.

Methods, formulations, and devices for providing transdermal or transmucosal delivery of active agents to subjects in need thereof. The formulations and methods treat symptoms of hormonal disorders including hypogonadism, female sexual desire disorder, female menopausal disorder, and adrenal insufficiency.

A nutritional composition and method of use that improves the net balance in skeletal muscle by targeting both the synthetic and breakdown processes. The disclosed composition provides for improved protein intake to increase skeletal muscle protein accretion in stressed patients who are at risk for the development of renal insufficiency by stimulating protein synthesis.

The invention is directed to tricyclic benzodiazepines useful as vasopressin receptor antagonists for treating conditions involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising tricyclic benzodiazepines of the present invention and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

The present invention relates to an improved method of administration of glucocorticoid based compositions in glucocorticoid replacement therapies enabling an objectively based regimen for administration enabling correct individual dosing of glucocorticoids resulting in an optimised individual replacement therapy and thus an improved long-term outcome for patients with temporary or chronic adrenal insufficiency.

An application of Japanese St. john's-wort herb or its extract in preparing the medicines for preventing nephritis and renal insufficiency is disclosed.

The invention discloses a traditional Chinese medicine composition for treating the yang insufficiency of both the spleen and the kidney. The traditional Chinese medicine composition is mainly prepared through the following raw materials in parts by weight: 10-20 parts of poria cocos, 10-20 parts of paeonia lactiflora, 5-15 parts of rhizoma atractylodis macrocephalae, 10-20 parts of ginger and 5-15 parts of radix aconiti carmichaeli. The medicine disclosed by the invention is scientifically blended by selecting 5 natural traditional Chinese medicines, is simple in formula, achieves the effects of promoting blood circulation to remove blood stasis, warmly invigorating the liver and the kidney and strengthening muscles and bones through the synergistic effect of crude medicines, is quick in effect without toxic or side effect, simple in preparation method, convenient to take and low in cost and achieves the effective rate more than 95%.

The invention provides autologous stem cells for treating renal insufficiency and a preparation method thereof. In the preparation method, autologous progenitor cells for treating renal insufficiency are generated by induced differentiation of adipose-derived stem cells which are obtained by separation from the adipose tissue of a patient, purification and amplification culture. The resource of the autologous progenitor cells is rich, the autologous progenitor cells can be obtained conveniently, and the preparation method is simple, convenient, easy, economic and practical. The prepared stem cells are subjected to autotransfusion to treat renal insufficiency with obvious treatment effect, high safety, no immunological rejection, no obvious toxic or side effects, no adverse reaction and less pain in patients. The invention provides a brand-new treatment means for patients with renal insufficiency and has a profound active significance.

The invention relates to the use of a medicinal capsule for treating cardiac functional insufficiency and cardiac failure, wherein the medicinal preparation comprises the formulations of red ginseng 300g, Ligusticum wallichii 500g and cassia twig 200g.

The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.

The invention relates to a Yang-Activating Decoction medicine oral preparation prepared from seven Chinese traditional medicines including prepared rhizome of rehmannia, and a preparation method thereof. The oral preparation is prepared from mixed extracts (extract or dried powder and volatile oil) of prepared rhizome of rehmannia, white mustard seed, carrageenin, cinnamon, dry ginger charcoal, ephedra, and licorice root, and pharmaceutically acceptable carrier or excipient as ground substance in the conventional preparation method. The oral preparation can be mainly used for treating dorsal furuncle due to yang insufficiency, blood deficiency, accumulation of pathogenic cold and phlegm stagnation. The long term clinical application of the prescription indicates that the oral preparation has good curative effect on dorsal furuncle due to yang insufficiency, accumulation of pathogenic cold, menoxenia due to blood deficiency, and phlegm dampness and stagnation in joint and meridian.

An application of Japanese St. john's-wort herb or its extract in preparing the medicines for preventing nephritis and renal insufficiency is disclosed.

The invention relates to traditional Chinese medicine composition for treating chronic nephritis and renal insufficiency. The traditional Chinese medicine composition is prepared from the following substances in parts by weight: 18-22 parts of rhubarb, 12-30 parts of mole crickets, 10-15 parts of centipedes, 40-50 parts of radix pseudostellariae, 25-35 parts of coastal glehnia roots, 23-30 parts of ophiopogon japonicas, 6-8 parts of Chinese magnoliavine fruits, 30-40 parts of milkvetch roots, 20-25 parts of Chinese angelica, 20-25 parts of stir-fried largehead atractylodes rhizomes, 20-25 parts of poria cocos, 20-25 parts of dried tangerine peels, 20-25 parts of uncooked coix seeds, 20-25 parts of common macrocarpium fruits, 30-35 parts of Chinese taxillus herbs, 20-25 parts of stir-fried spina date seeds, 30-35 parts of spreading hedyotis herbs, 30-35 parts of honeysuckle flowers, 30-35 parts of charred triplet, 20-25 parts of rice beans, 20-25 parts of dandelions, 25-30 parts of glossy privet fruits. 25-30 parts of dodder seeds, 30-40 parts of fructus lycii, 20-30 parts of semen plantaginis, 20-30 parts of cherokee rose fruits and 30-40 parts of salvia miltiorrhiza. The traditional Chinese medicine composition takes effect quickly, the treatment course is short, the efficiency is high, the cost is low, and toxic and side effects are avoided.

The present invention relates to a composition of at least one protease and a mode of application for treating patients suffering from pancreatic enzyme insufficiency, pancreatitis or cystic fibrosis. The composition of enzymes comprises at least one protease which has a pH optimum below 5.0 and wherein said protease is further active in the presence of pepsin. In a preferred embodiment, said protease is of microbial origin.

The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression.